Switdapa-m
Each film-coated tablet contains dapagliflozin + metformin
Blister pack of 1 x 15 tablets.
Dapagliflozin 10 mg + metformin 500 mg is a fixed-dose combination oral antidiabetic medication for adults with type 2 diabetes mellitus (t2dm). It provides dual action—dapagliflozin promotes urinary glucose excretion by inhibiting sodium-glucose cotransporter 2 (sglt2), and metformin reduces hepatic glucose production and increases insulin sensitivity for optimal glycemic control. This combination has proven cardiovascular and renal protective benefits, supports weight loss, and reduces the risk of diabetic complications.
Adults (≥18 years) diagnosed with type 2 diabetes mellitus. Not recommended for patients with type 1 diabetes or severe renal impairment.
As advised by the treating physician or endocrinologist, tailored to individual patient response.
Indicated for the management of type 2 diabetes mellitus: improves blood sugar control, lowers hba1c, reduces cardiovascular risk, and slows progression of diabetic kidney disease (ckd). Also beneficial in heart failure (hfref and hfpef) and for weight management. Combination therapy provides superior metabolic improvements compared to monotherapy.
Common side effects include genital or urinary tract infections, increased urination, nasopharyngitis, sore throat, headache, nausea, vomiting, diarrhoea, runny or stuffy nose, and mild gastrointestinal upset. Risk of hypoglycaemia is minimal but may increase when used with insulin or sulfonylureas. Most effects are mild, self-limiting, and well-tolerated.
Dapagliflozin inhibits sglt2 in proximal renal tubules, increasing urinary glucose excretion and promoting osmotic diuresis. Metformin lowers hepatic glucose output and increases peripheral glucose uptake. The combination enhances overall glycemic control, insulin sensitivity, supports weight loss, and contributes to cardiovascular and renal health.
